All Posts

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

Summary:

AUPH PR on settlement of patent disputes with the Indian generic company, Sun is very brief. See entire substantive portion of press...

AUPH PR on settlement of patent disputes with the Indian generic company, Sun is very brief. See entire substantive portion of press release below*. Nothing more filed with SEC.

AUPH PR on settlement of patent disputes with the Indian generic company, Sun is very brief. See entire substantive portion of press release below*. Nothing more filed with SEC. High level of settlement is the following**: Sun gets out of patent infringement litigation and gets covenant not to sue from AUPH for AUPH's '375 and '871 Patents covering Sun's Cequa product for DED Sun agrees to drop USPTO challenge (IPR) against AUPH's '036 Patent '036 Patent relates to using eGFR

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

TGTX BRIUMVI (Ublituximab) approved for MS on 12/28/2022! See the new label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/76...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...